Alector Inc (NAS:ALEC)

$ 5.49 -0.16 (-2.83%) Market Cap: 529.15 Mil Enterprise Value: 20.05 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 81/100

Q4 2023 Alector Inc Earnings Call Transcript
Feb 27, 2024

$7.01 (+8.18%)

Earnings
Alector Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Q2 2023 Alector Inc Earnings Call Transcript
Aug 03, 2023

$6.63 (+0.38%)

Earnings
Alector Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
H.C. Wainwright with Alector Transcript
May 24, 2023
Alector Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Alector Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Alector Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Alector Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Alector Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Alector Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Alector Inc to Present New AL001 Data- Conference Call Transcript
Mar 15, 2022
Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) Transcript
Mar 08, 2022
Alector Inc to Present to Discuss Data Presented at 2021 Clinical Trials on Alzheimer's Disease Meeting Transcript
Nov 12, 2021
Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Alector Inc at Citi BioPharma Conference (Virtual)- Panel: What's Next for Neurodegenerative Diseases Transcript
Sep 08, 2021
Alector Inc to Review the AL001 Phase 2 Results- Conference Call Transcript
Jul 29, 2021
Alector Inc to Discuss Collaboration with GlaxoSmithKline PLC for AL001 & AL101 Call Transcript
Jul 02, 2021
Alector Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 14, 2021
Alector Inc to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia Transcript
Jun 11, 2021
Alector Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Alector Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Alector Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021
Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Alector Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2020
Alector Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Alector Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Alector Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Alector, Inc. - Special Call Transcript
Dec 13, 2019
Alector Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Alector Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019

Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 07:10PM GMT

Release Date Price: $13.41 (-9.70%)

Transcript

Yaron Benjamin Werber

Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Welcome and good afternoon. Thanks, everybody, once again for joining us at the 42nd Annual Cowen Healthcare Conference. I'm Yaron Werber, one of the biotech analyst at Cowen. And it's a great pleasure to moderate the orphan CNS therapies panel with my colleagues, Brendan Smith and Lyla Youssef. We really have a terrific lineup today and a lot to talk about. We have from Annexon, Doug Love, who's the CEO; Geoff MacKay, who's the CEO of AVROBIO; we have Bobby Gaspar, who's the CEO of Orchard; Bruce Goldsmith, who's the CEO of Passage Bio; Emil Kakkis, who's the President and CEO of Ultragenyx; and Arnon Rosenthal, who is the CEO of Alector is going to be joining momentarily. So welcome, everybody, and thanks for joining us. We appreciate it.

So let's start. What we're going to do is we're going to talk first about a couple of maybe very broad drug development topics in orphan neurology, and then we'll do a round robin and dive into each company specifically. Most of you are developing drugs

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.